A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Conditions
Colon | Rectum
Phase I
Volunteers
Health Professionals
What is the purpose of this trial?
This randomized phase 1b/2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.
- Trial withArcus Biosciences, Inc.
- Start Date01/12/2022
- End Date09/20/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Andrea Brennan
- Andrea Martelli
- Anna Fleischman
- Armand Russo, MD
- Brooke Chaves
- David Witt, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kristen Hoxie
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pamela Kunz, MD
- Pawan Karanam, MD
- Sara Anastasio, RN
- Stacey Stein, MD
- Teresa White
- Virginia Syombathy
- Xuanthao Thi Nguyen
- Last Updated01/13/2022
- Study HIC#2000029908